Daily Sepsis Research Analysis
Analyzed 45 papers and selected 3 impactful papers.
Summary
Top findings include a double-blind RCT showing neostigmine reduces inflammatory cytokines and signals a mortality benefit in septic shock, a universal SERS-based antimicrobial susceptibility test delivering species-independent results within 5 hours, and a multicohort machine learning model that predicts sepsis-related liver injury early with strong internal and external performance.
Research Themes
- Cholinergic anti-inflammatory modulation in septic shock
- Rapid, species-independent antimicrobial susceptibility testing
- Early risk stratification of organ dysfunction via machine learning
Selected Articles
1. Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial.
In a single-center double-blind RCT, continuous neostigmine infusion (0.2 mg/h for 5 days) significantly reduced TNF-α levels versus placebo (day-5 40±36 vs 67±43 pg/mL; p=0.002), improved SOFA scores (p<0.001), and was associated with lower 28-day mortality (26% vs 54%; p=0.02). Findings support cholinergic anti-inflammatory pathway activation in septic shock.
Impact: This is a randomized, double-blind, placebo-controlled trial reporting biomarker and mortality signals with an accessible, repurposed drug targeting a defined immunomodulatory pathway.
Clinical Implications: Neostigmine may serve as an adjuvant therapy in septic shock to dampen hyperinflammation and potentially improve survival; multicenter trials are warranted to confirm efficacy and safety.
Key Findings
- Day-5 TNF-α levels were lower with neostigmine vs placebo (40±36 vs 67±43 pg/mL; p=0.002).
- SOFA scores decreased significantly from day 1 to day 5 with neostigmine (p<0.001).
- 28-day mortality was lower in the neostigmine group (26%) vs control (54%; p=0.02).
Methodological Strengths
- Prospective, randomized, double-blind, placebo-controlled design
- Pre-registered trial (CTRI/2023/07/055054) with clinically meaningful endpoints
Limitations
- Single-center study with unspecified sample size
- Primary endpoint was biomarker reduction; mortality analysis may be underpowered
Future Directions: Conduct adequately powered multicenter RCTs assessing patient-centered outcomes, optimal dosing/duration, and safety across diverse septic shock phenotypes.
OBJECTIVE: The cholinergic anti-inflammatory pathway (ChAP) is the key regulator of the dysregulated cytokine storm in sepsis, with acetylcholine acting on alpha-7 nicotinic acetylcholine receptors (α7nAChRs) to suppress excessive inflammation. The objective of this study was to evaluate whether neostigmine administration modulates the inflammatory response in sepsis by enhancing cholinergic anti-inflammatory activity. DESIGN: A single-center, prospective, randomized, double-blinded, placebo-controlled study. SETTIN
2. SERS-Based Universal AST: Rapid Treatment Guidance for Blood-Culture Bacteria before Species Identification.
SERS-Uni-AST delivers species-independent AST by monitoring antibiotic-evoked metabolic changes via label-free SERS. In 191 clinical blood-culture isolates (43 species; 7 antibiotics), it achieved 92% categorical agreement with standard methods within 5 hours, performing across Gram-positive and Gram-negative bacteria including ESKAPE pathogens.
Impact: This platform bypasses species identification and substantially shortens AST turnaround, enabling earlier targeted therapy in sepsis workflows.
Clinical Implications: Microbiology labs could implement species-agnostic AST to align with Surviving Sepsis Campaign goals by reducing time to effective therapy and potentially curbing broad-spectrum overuse.
Key Findings
- Achieved 92% categorical agreement with reference AST in 191 clinical isolates spanning 43 species and 7 antibiotics.
- Provided results within 5 hours, eliminating the need for prior species identification.
- Demonstrated robust performance across Gram-positive and Gram-negative bacteria, including ESKAPE pathogens, with a predefined species-independent decision threshold.
Methodological Strengths
- Species-independent decision framework validated on a diverse, clinically derived isolate set
- Rapid, label-free SERS readout with standardized workflow
Limitations
- Validation focused on isolates from positive blood cultures rather than direct-from-blood testing
- Clinical impact on time-to-effective therapy and patient outcomes was not assessed
Future Directions: Prospective clinical studies linking SERS-Uni-AST implementation to time-to-appropriate therapy, antibiotic stewardship metrics, and patient outcomes; expansion of antibiotic panels and direct-from-blood workflows.
Rapid antimicrobial susceptibility testing (AST) is essential for managing bloodstream infections with high mortality, yet most current methods require prior identification of bacterial species, limiting their speed and applicability. To address these limitations, we developed SERS-Uni-AST, a species-independent platform based on surface-enhanced Raman scattering (SERS) that monitors the metabolic responses of bacteria to antibiotics through label-free detection. This approach eliminates the ne
3. Early risk stratification of sepsis-related liver injury via machine learning: a multicohort study.
Using MIMIC-IV (n=9,434) with external validation (n=120), a Random Forest model predicted SRLI early with ROC-AUC 0.867 internally and 0.862 externally. SHAP identified total bilirubin, INR, SOFA, LODS, and prothrombin time as top early predictors, and decision curve analysis supported clinical utility.
Impact: Large-scale, externally validated ML risk stratification offers interpretable, actionable predictors for early hepatic monitoring in sepsis.
Clinical Implications: Early identification of SRLI risk using routine labs (e.g., PT/INR, bilirubin) could trigger preventive strategies, closer monitoring, and hepatology consultation, potentially improving outcomes.
Key Findings
- Random Forest achieved ROC-AUC 0.867 (internal) and 0.862 (external) for early SRLI prediction; PR-AUC 0.392 (internal) and 0.735 (external).
- Top predictors within 24 h included total bilirubin, INR, SOFA, LODS, and prothrombin time (via SHAP).
- Decision curve analysis demonstrated positive net benefit across a broad range of risk thresholds.
Methodological Strengths
- Large internal cohort with external validation
- Explainable ML (SHAP) and decision curve analysis for clinical interpretability and utility
Limitations
- Retrospective design with potential residual confounding
- External validation cohort was relatively small (n=120), affecting generalizability
Future Directions: Prospective validation across diverse ICUs, integration into EHR for real-time alerts, and interventional studies testing SRLI-targeted early management triggered by model predictions.
BACKGROUND: Sepsis-related liver injury (SRLI) is associated with poor prognosis and high morbidity in septic patients. Early mitigation of liver injury is crucial for improving outcomes in the critically ill. However, early detection and intervention remain challenging, due in part to the lack of effective diagnostic and screening strategies. This study aimed to apply machine learning (ML) approaches to identify significant predictors for the onset of SRLI, with the goal of facilitating early